Table of Contents
Cancers, Volume 11, Issue 3 (March 2019)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) The increasing use of PD-1 inhibitors is causing immune-related adverse events that have never been [...] Read more. The increasing use of PD-1 inhibitors is causing immune-related adverse events that have never been observed with conventional chemotherapies. Their exact pathophysiology remains unclear, but their early recognition and treatment are crucial both for the resolution of symptoms and for treatment management. Immune-related neurological toxicities associated with PD-1 inhibitors are rarely reported, but as the use of these agents increases, it is important for clinicians to be aware of such serious potential side effects, which may have lasting consequences. Even if these side effects are rare and often respond well to steroid treatment, they can appear in different patterns and not always have a favorable outcome. Consultations with different specialists are necessary to classify and successfully treat these conditions, as many patients have a reasonable chance of long-term disease control. View this paper